This study will help researchers answer questions about the drug mavorixafor.
Mavorixafor pills are taken by mouth.
In earlier studies, mavorixafor was well tolerated in over 200 people, including healthy volunteers and people with cancer or primary immunodeficiencies.
This is a Phase 1b study, which means participants with WM can help researchers learn what dosage of mavorixafor is well-tolerated in combination with ibrutinib.
Everyone in this study will take varying doses of mavorixafor along with ibrutinib, an FDA-approved treatment for WM.
The study will last about 2 years.
There is no cost for people in the study. Treatment, travel and lodging costs are covered by X4 Pharaceuticals.
X4 Pharmaceuticals is conducting the trial in collaboration with The Leukemia & Lymphoma Society.
Medical study centers are in Boston, Denver and Houston, and the study may involve home health care and virtual check-ups.